VALID TRIAL
Both CHIA and your personal trial have the following criteria:
╒════════════════════════════════════════════════════╤════════════════════════════════════════════════════╤═════════╕
│ Personal Criteria                                  │ CHIA Criteria                                      │   Score │
╞════════════════════════════════════════════════════╪════════════════════════════════════════════════════╪═════════╡
│ Informed consent as documented by signature (see   │ Informed consent as documented by signature (see   │     100 │
│ informed consent form)                             │ informed consent form)                             │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Age range: 18-45 years                             │ Age range: 18-45 years                             │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Previously treated patients, with failure or       │ Previously treated patients, with failure or       │     100 │
│ intolerance to first-line therapy, or relapse      │ intolerance to first-line therapy, or relapse      │         │
│ after first-line therapy, i.e. corticosteroids,    │ after first-line therapy, i.e. corticosteroids,    │         │
│ intravenous immunoglobulin (IVIG), or anti-D       │ intravenous immunoglobulin (IVIG), or anti-D       │         │
│ immunoglobulins                                    │ immunoglobulins                                    │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Adults older than 45 and children younger than 18  │ Adults older than 45 and children younger than 18  │     100 │
│ years                                              │ years                                              │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Platelet count higher than 30x109/l at time of     │ Platelet count higher than 30x109/l at time of     │     100 │
│ screening                                          │ screening                                          │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Suspicion of secondary ITP                         │ Suspicion of secondary ITP                         │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Positive family history for ITP                    │ Positive family history for ITP                    │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Presence or history of autoimmune disease as       │ Presence or history of autoimmune disease as       │     100 │
│ judged by the investigator                         │ judged by the investigator                         │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Hepatosplenomegaly                                 │ Hepatosplenomegaly                                 │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Presence or history of relevant hepatic disease as │ Presence or history of relevant hepatic disease as │     100 │
│ judged by the investigator                         │ judged by the investigator                         │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Presence or history of thromboembolic disease as   │ Presence or history of thromboembolic disease as   │     100 │
│ judged by the investigator                         │ judged by the investigator                         │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Patients with splenectomy                          │ Patients with splenectomy                          │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Women who are pregnant or breast feeding           │ Women who are pregnant or breast feeding           │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Intention to become pregnant during the course of  │ Intention to become pregnant during the course of  │     100 │
│ the study                                          │ the study                                          │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Lack of safe double contraception (see 7.1)        │ Lack of safe double contraception (see 7.1)        │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Any vaccination 2 weeks prior start of the study   │ Any vaccination 2 weeks prior start of the study   │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Drugs with a known impact on the immune system or  │ Drugs with a known impact on the immune system or  │     100 │
│ on platelet function must be recorded and an       │ on platelet function must be recorded and an       │         │
│ exclusion of the study should be discussed with    │ exclusion of the study should be discussed with    │         │
│ the study center                                   │ the study center                                   │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Known or suspected non-compliance, drug or alcohol │ Known or suspected non-compliance, drug or alcohol │     100 │
│ abuse                                              │ abuse                                              │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Inability to follow the procedures of the study,   │ Inability to follow the procedures of the study,   │     100 │
│ e.g. due to language problems, psychological       │ e.g. due to language problems, psychological       │         │
│ disorders, dementia of the study subject           │ disorders, dementia of the study subject           │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Participation in another study with                │ Participation in another study with                │     100 │
│ investigational drug within the 30 days preceding  │ investigational drug within the 30 days preceding  │         │
│ and during the present study                       │ and during the present study                       │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Previous enrolment into the current study          │ Previous enrolment into the current study          │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Previous treatment with romiplostim or eltrombopag │ Previous treatment with romiplostim or eltrombopag │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Hypersensitivity to the active substance or to any │ Hypersensitivity to the active substance or to any │     100 │
│ of the excipients or to E. coli derived proteins   │ of the excipients or to E. coli derived proteins   │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Enrolment of the investigator, his/her family      │ Enrolment of the investigator, his/her family      │     100 │
│ members, employees and other dependent persons     │ members, employees and other dependent persons     │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Primary ITP according to the definition of         │ Primary ITP according to the definition of         │      99 │
│ Rodeghiero et al. (52) and a platelet count of     │ Rodeghiero et al. (52) and a platelet count of     │         │
│ \<30x109/l                                         │ <30x109/l                                          │         │
╘════════════════════════════════════════════════════╧════════════════════════════════════════════════════╧═════════╛

Only your personal trial has the following criteria:
╒═══════════════════════════════════╤════════════════════════╤═════════╕
│ Personal Criteria                 │ CHIA Criteria          │   Score │
╞═══════════════════════════════════╪════════════════════════╪═════════╡
│ Must have minimum age of 18 Years │ Age range: 18-45 years │      47 │
├───────────────────────────────────┼────────────────────────┼─────────┤
│ Must have maximum age of 45 Years │ Age range: 18-45 years │      47 │
╘═══════════════════════════════════╧════════════════════════╧═════════╛

CHIA has no unique criteria

Levenshtein Ratio of Entire trial at once: 98
Average Levenshtein Ratio of individual lines: 96.03703703703704
OverAll Ratio: 97.01851851851852
